{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:42:56Z","timestamp":1792784576482,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Shanghai Municipal Health Commission","award":["202140069"],"award-info":[{"award-number":["202140069"]}]},{"name":"Young Clinical Scientist Training Program at Shanghai Medical College of Fudan University.","id":[{"id":"https:\/\/ror.org\/01zntxs11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40266-024-01155-4","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T23:55:34Z","timestamp":1729900534000},"page":"897-906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pilocarpine in the Treatment of Presbyopia: Progress, Issues, and Future Prospects"],"prefix":"10.1007","volume":"41","author":[{"given":"Xiuwen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taomin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingtao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"1155_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/aos.12308","volume":"92","author":"AD Goertz","year":"2014","unstructured":"Goertz AD, Stewart WC, Burns WR, et al. Review of the impact of presbyopia on quality of life in the developing and developed world. Acta Ophthalmol. 2014;92:497\u2013500. https:\/\/doi.org\/10.1111\/aos.12308.","journal-title":"Acta Ophthalmol"},{"key":"1155_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1475-1313.2007.00484.x","volume":"27","author":"H Radhakrishnan","year":"2007","unstructured":"Radhakrishnan H, Charman WN. Age-related changes in static accommodation and accommodative miosis. Ophthalmic Physiol Opt. 2007;27:342\u201352. https:\/\/doi.org\/10.1111\/j.1475-1313.2007.00484.x.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1155_CR3","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.ophtha.2018.04.013","volume":"125","author":"TR Fricke","year":"2018","unstructured":"Fricke TR, Tahhan N, Resnikoff S, et al. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis, and modelling. Ophthalmology. 2018;125:1492\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.013.","journal-title":"Ophthalmology"},{"key":"1155_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.51329\/mehdioptometry110","volume":"1","author":"B Orman","year":"2021","unstructured":"Orman B, Benozzi G. Overview of pharmacological treatments for presbyopia. Med Hypothesis Discov Innov Optom. 2021;1:67\u201377. https:\/\/doi.org\/10.51329\/mehdioptometry110.","journal-title":"Med Hypothesis Discov Innov Optom."},{"key":"1155_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3928\/1081597x-20210408-04","volume":"37","author":"MB McDonald","year":"2021","unstructured":"McDonald MB, Mychajlyszyn A, Mychajlyszyn D, Klyce SD. Advances in corneal surgical and pharmacological approaches to the treatment of presbyopia. J Refract Surg. 2021;37:20\u20137. https:\/\/doi.org\/10.3928\/1081597x-20210408-04.","journal-title":"J Refract Surg"},{"key":"1155_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3928\/1081597X-20191010-04","volume":"35","author":"R Montes-Mico","year":"2019","unstructured":"Montes-Mico R, Charman WN. Pharmacological strategies for presbyopia correction. J Refract Surg. 2019;35:803\u201314. https:\/\/doi.org\/10.3928\/1081597X-20191010-04.","journal-title":"J Refract Surg"},{"key":"1155_CR7","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/OPTH.S259011","volume":"15","author":"JA Katz","year":"2021","unstructured":"Katz JA, Karpecki PM, Dorca A, et al. Presbyopia: a review of current treatment options and emerging therapies. Clin Ophthalmol. 2021;15:2167\u201378. https:\/\/doi.org\/10.2147\/OPTH.S259011.","journal-title":"Clin Ophthalmol"},{"key":"1155_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/OPX.0000000000001924","volume":"99","author":"G Westheimer","year":"2022","unstructured":"Westheimer G. Topical review: pilocarpine-induced miosis as help for early presbyopes? Optom Vis Sci. 2022;99:632\u20134. https:\/\/doi.org\/10.1097\/OPX.0000000000001924.","journal-title":"Optom Vis Sci"},{"key":"1155_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/ICU.0000000000000864","volume":"33","author":"BB Meghpara","year":"2022","unstructured":"Meghpara BB, Lee JK, Rapuano CJ, et al. Pilocarpine 1.25% and the changing landscape of presbyopia treatment. Curr Opin Ophthalmol. 2022;33:269\u201374. https:\/\/doi.org\/10.1097\/ICU.0000000000000864.","journal-title":"Curr Opin Ophthalmol"},{"key":"1155_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40266-022-01002-4","volume":"40","author":"B Orman","year":"2023","unstructured":"Orman B, Benozzi G. Pharmacological treatments for presbyopia. Drugs Aging. 2023;40:105\u201316. https:\/\/doi.org\/10.1007\/s40266-022-01002-4.","journal-title":"Drugs Aging"},{"key":"1155_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.preteyeres.2018.09.004","volume":"68","author":"JS Wolffsohn","year":"2019","unstructured":"Wolffsohn JS, Davies LN. Presbyopia: effectiveness of correction strategies. Prog Retin Eye Res. 2019;68:124\u201343. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.09.004.","journal-title":"Prog Retin Eye Res"},{"key":"1155_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/08820538.2019.1586966","volume":"34","author":"SY Park","year":"2019","unstructured":"Park SY, Choi YJ, Jung JW, et al. Clinical efficacy of pinhole soft contact lenses for the correction of presbyopia. Semin Ophthalmol. 2019;34:106\u201314. https:\/\/doi.org\/10.1080\/08820538.2019.1586966.","journal-title":"Semin Ophthalmol."},{"key":"1155_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jcrs.2010.10.044","volume":"37","author":"AK Dexl","year":"2011","unstructured":"Dexl AK, Seyeddain O, Riha W, et al. Reading performance after implantation of a small-aperture corneal inlay for the surgical correction of presbyopia: two-year follow-up. J Cataract Refract Surg. 2011;37:525\u201331. https:\/\/doi.org\/10.1016\/j.jcrs.2010.10.044.","journal-title":"J Cataract Refract Surg"},{"key":"1155_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/cphy.c140014","volume":"5","author":"DH McDougal","year":"2015","unstructured":"McDougal DH, Gamlin PD. Autonomic control of the eye. Compr Physiol. 2015;5:439\u201373. https:\/\/doi.org\/10.1002\/cphy.c140014.","journal-title":"Compr Physiol"},{"key":"1155_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jamaophthalmol.2022.0059","volume":"140","author":"GOT Waring","year":"2022","unstructured":"Waring GOT, Price FW Jr, Wirta D, et al. Safety and efficacy of AGN-190584 in individuals with presbyopia: the GEMINI 1 phase 3 randomized clinical trial. JAMA Ophthalmol. 2022;140:363\u201371. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.0059.","journal-title":"JAMA Ophthalmol."},{"key":"1155_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/j.jcrs.0000000000001313","volume":"50","author":"CW Lievens","year":"2024","unstructured":"Lievens CW, Hom MM, McLaurin EB, et al. Pilocarpine HCl 1.25% for treatment of presbyopia after laser vision correction: pooled analysis of two phase 3 randomized trials (GEMINI 1 and 2). J Cataract Refract Surg. 2024;50:57\u201363. https:\/\/doi.org\/10.1097\/j.jcrs.0000000000001313.","journal-title":"J Cataract Refract Surg"},{"key":"1155_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/08164622.2023.2279189","volume":"107","author":"GOT Waring","year":"2024","unstructured":"Waring GOT, Brujic M, McGee S, et al. Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance. Clin Exp Optom. 2024;107:665\u201372. https:\/\/doi.org\/10.1080\/08164622.2023.2279189.","journal-title":"Clin Exp Optom"},{"key":"1155_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ajo.2023.05.008","volume":"253","author":"S Kannarr","year":"2023","unstructured":"Kannarr S, El-Harazi SM, Moshirfar M, et al. Safety and efficacy of twice-daily pilocarpine HCl in presbyopia: the Virgo phase 3, randomized, double-masked, controlled study. Am J Ophthalmol. 2023;253:189\u2013200. https:\/\/doi.org\/10.1016\/j.ajo.2023.05.008.","journal-title":"Am J Ophthalmol"},{"key":"1155_CR19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s40123-024-00935-w","volume":"13","author":"BM Shafer","year":"2024","unstructured":"Shafer BM, McGee SR, Ifantides C, et al. Understanding perspectives on presbyopia and use of pilocarpine HCl 1.25% twice daily from participants of the phase 3 VIRGO Study. Ophthalmol Ther. 2024;13:1723\u201342. https:\/\/doi.org\/10.1007\/s40123-024-00935-w.","journal-title":"Ophthalmol Ther"},{"key":"1155_CR20","unstructured":"Socea S, Mimouni M, Andreja V, Blumenthal EZ. Drops for presbyopia: results of CSF-1, a multicenter randomized double-masked placebo-controlled crossover study. Invest Ophth Vis Sci. 2019;60."},{"key":"1155_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.clinthera.2023.12.005","volume":"46","author":"E Holland","year":"2024","unstructured":"Holland E, Karpecki P, Fingeret M, et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials. Clin Ther. 2024;46:104\u201313. https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.005.","journal-title":"Clin Ther"},{"key":"1155_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.6026\/973206300200532","volume":"20","author":"S Petkar","year":"2024","unstructured":"Petkar S, Chaitra MC. Correction of presbyopia using 0.5% pilocarpine eye drops among Indians. Bioinformation. 2024;20:532\u20136. https:\/\/doi.org\/10.6026\/973206300200532.","journal-title":"Bioinformation"},{"key":"1155_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100065","volume":"1","author":"FW Price Jr","year":"2021","unstructured":"Price FW Jr, Hom M, Moshirfar M, et al. Combinations of pilocarpine and oxymetazoline for the pharmacological treatment of presbyopia: two randomized phase 2 studies. Ophthalmol Sci. 2021;1: 100065. https:\/\/doi.org\/10.1016\/j.xops.2021.100065.","journal-title":"Ophthalmol Sci."},{"key":"1155_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0014-2999(01)00977-3","volume":"419","author":"Y Yu","year":"2001","unstructured":"Yu Y, Kawarai M, Koss MC. Histamine H3 receptor-mediated inhibition of sympathetically evoked mydriasis in rats. Eur J Pharmacol. 2001;419:55\u20139.","journal-title":"Eur J Pharmacol"},{"key":"1155_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.clinthera.2005.04.011","volume":"27","author":"JV Greiner","year":"2005","unstructured":"Greiner JV, Udell IJ. A comparison of the clinical efficacy of pheniramine maleate\/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Clin Ther. 2005;27:568\u201377. https:\/\/doi.org\/10.1016\/j.clinthera.2005.04.011.","journal-title":"Clin Ther"},{"key":"1155_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/0301-4738.103773","volume":"60","author":"S Sarkar","year":"2012","unstructured":"Sarkar S, Hasnat AM, Bharadwaj SR. Revisiting the impact of phenylephrine hydrochloride on static and dynamic accommodation. Indian J Ophthalmol. 2012;60:503\u20139. https:\/\/doi.org\/10.4103\/0301-4738.103773.","journal-title":"Indian J Ophthalmol"},{"key":"1155_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40123-016-0050-x","volume":"5","author":"A Renna","year":"2016","unstructured":"Renna A, Vejarano LF, De la Cruz E, Alio JL. Pharmacological treatment of presbyopia by novel binocularly instilled eye drops: a pilot study. Ophthalmol Ther. 2016;5:63\u201373. https:\/\/doi.org\/10.1007\/s40123-016-0050-x.","journal-title":"Ophthalmol Ther"},{"key":"1155_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40123-018-0154-6","volume":"8","author":"V Vargas","year":"2019","unstructured":"Vargas V, Vejarano F, Ali\u00f3 JL. Near vision improvement with the use of a new topical compound for presbyopia correction: a prospective, consecutive interventional non-comparative clinical study. Ophthalmol Ther. 2019;8:31\u20139. https:\/\/doi.org\/10.1007\/s40123-018-0154-6.","journal-title":"Ophthalmol Ther"},{"key":"1155_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s40123-023-00648-6","volume":"12","author":"F Vejarano","year":"2023","unstructured":"Vejarano F, Alio J, Iribarren R, Lanca C. Non-miotic improvement in binocular near vision with a topical compound formula for presbyopia correction. Ophthalmol Ther. 2023;12:1013\u201324. https:\/\/doi.org\/10.1007\/s40123-023-00648-6.","journal-title":"Ophthalmol Ther"},{"key":"1155_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/s0161-6420(82)34866-6","volume":"89","author":"TJ Zimmerman","year":"1982","unstructured":"Zimmerman TJ, Wheeler TM. Miotics: side effects and ways to avoid them. Ophthalmology. 1982;89:76\u201380. https:\/\/doi.org\/10.1016\/s0161-6420(82)34866-6.","journal-title":"Ophthalmology"},{"key":"1155_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1167\/iovs.06-0380","volume":"48","author":"LA Ostrin","year":"2007","unstructured":"Ostrin LA, Glasser A. Effects of pharmacologically manipulated amplitude and starting point on Edinger-Westphal-stimulated accommodative dynamics in rhesus monkeys. Invest Ophthalmol Vis Sci. 2007;48:313\u201320. https:\/\/doi.org\/10.1167\/iovs.06-0380.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1155_CR32","first-page":"3","volume":"1","author":"J Benozzi","year":"2012","unstructured":"Benozzi J, Benozzi G, Orman B. Presbyopia: a new potential pharmacological treatment. Med Hypothesis Discov Innov Ophthalmol. 2012;1:3\u20135.","journal-title":"Med Hypothesis Discov Innov Ophthalmol."},{"key":"1155_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/tvst.9.7.25","volume":"9","author":"G Benozzi","year":"2020","unstructured":"Benozzi G, Perez C, Leiro J, et al. Presbyopia treatment with eye drops: an eight year retrospective study. Transl Vis Sci Technol. 2020;9:25. https:\/\/doi.org\/10.1167\/tvst.9.7.25.","journal-title":"Transl Vis Sci Technol."},{"key":"1155_CR34","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s00417-021-05138-8","volume":"259","author":"G Benozzi","year":"2021","unstructured":"Benozzi G, Cortina ME, Gimeno E, et al. A multicentric study of pharmacological treatment for presbyopia. Graefes Arch Clin Exp Ophthalmol. 2021;259:2441\u201350. https:\/\/doi.org\/10.1007\/s00417-021-05138-8.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1155_CR35","doi-asserted-by":"publisher","DOI":"10.4172\/2324-8599.1000218","author":"S Facal","year":"2018","unstructured":"Facal S, Leiro J, Gualtieri A, et al. Ocular surface evaluation in patients treated with pharmacological treatment for presbyopia. Int J Ophthalmic Pathol. 2018. https:\/\/doi.org\/10.4172\/2324-8599.1000218.","journal-title":"Int J Ophthalmic Pathol."},{"key":"1155_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/APO.0000000000000297","volume":"9","author":"A Grzybowski","year":"2020","unstructured":"Grzybowski A, Markeviciute A, Zemaitiene R. A review of pharmacological presbyopia treatment. Asia Pac J Ophthalmol (Phila). 2020;9:226\u201333. https:\/\/doi.org\/10.1097\/APO.0000000000000297.","journal-title":"Asia Pac J Ophthalmol (Phila)."},{"key":"1155_CR37","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40123-022-00482-2","volume":"11","author":"MA Jackson","year":"2022","unstructured":"Jackson MA, Giyanani J, Shabaik Y, et al. In vitro and in-eye comparison of commercial pilocarpine ophthalmic solution and an optimized, reformulated pilocarpine for presbyopia treatment. Ophthalmol Ther. 2022;11:869\u201379. https:\/\/doi.org\/10.1007\/s40123-022-00482-2.","journal-title":"Ophthalmol Ther"},{"key":"1155_CR38","first-page":"659","volume":"107","author":"T Tucker","year":"2023","unstructured":"Tucker T, Early J. Pilocarpine 1.25% ophthalmic solution (Vuity) for the treatment of presbyopia. Am Fam Physician. 2023;107:659\u201360.","journal-title":"Am Fam Physician"},{"key":"1155_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/ICB.0000000000001309","volume":"18","author":"EA Eton","year":"2024","unstructured":"Eton EA, Zhao PY, Johnson MW, et al. Rhegmatogenous retinal detachment following initiation of pilocarpine hydrochloride ophthalmic solution 1.25% for treatment of presbyopia. Retin Cases Brief Rep. 2024;18:98\u2013100. https:\/\/doi.org\/10.1097\/ICB.0000000000001309.","journal-title":"Retin Cases Brief Rep"},{"key":"1155_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ajo.2022.05.011","volume":"242","author":"H Al-Khersan","year":"2022","unstructured":"Al-Khersan H, Flynn HW Jr, Townsend JH. Retinal detachments associated with topical pilocarpine use for presbyopia. Am J Ophthalmol. 2022;242:52\u20135. https:\/\/doi.org\/10.1016\/j.ajo.2022.05.011.","journal-title":"Am J Ophthalmol"},{"key":"1155_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293066","volume":"18","author":"T Wakabayashi","year":"2023","unstructured":"Wakabayashi T, Mansour HA, Abishek RM, et al. Google Search Trends to assess public interest in and concern about Vuity for treating presbyopia. PLoS\u00a0One. 2023;18: e0293066. https:\/\/doi.org\/10.1371\/journal.pone.0293066.","journal-title":"PLoS\u00a0One"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01155-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01155-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01155-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T12:07:35Z","timestamp":1731326855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01155-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01155-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"6 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the Shanghai Municipal Health Commission (202140069) and the Young Clinical Scientist Training Program at Shanghai Medical College of Fudan University, Science and Technology Commission of Shanghai Municipality (No. 23ZR1409100).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xiuwen Zhang, Xiaomei Xiong, Haixin Zhang, Taomin Huang, and Xingtao Zhou have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by XZ, XX, HZ, TH, and XZ. The first draft of the manuscript was written by XZ and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}